Post-effective Amendment to an S-8 Filing (s-8 Pos)
April 02 2019 - 8:41AM
Edgar (US Regulatory)
As filed with the Securities and Exchange Commission on April 2, 2019
Registration No. 333-217831
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
Post-Effective Amendment No. 1
to
FORM
S-8
REGISTRATION STATEMENT NO.
333-217831
UNDER
THE
SECURITIES ACT OF 1933
IMMUNE DESIGN CORP.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
1616 Eastlake Ave. E., Suite 310
Seattle, Washington 98102
(206)
682-0645
|
|
26-2007174
|
(State or other jurisdiction
of incorporation)
|
|
(Address of principal executive
offices including zip code)
|
|
(I.R.S. Employer
Identification Number)
|
Immune Design Corp. 2014 Omnibus Incentive Plan
(Full title of the plan)
Copies to:
|
|
|
Geralyn Ritter
Secretary
Immune Design
Corp.
1616 Eastlake Ave. E., Suite 310
Seattle, Washington 98102
|
|
Barbara L. Becker
Saee Muzumdar
Gibson,
Dunn & Crutcher LLP
200 Park Avenue
New York, NY 10166-0193
|
(Name and address of agent for service)
(206)
682-0645
(Telephone number, including area code, of agent for service)
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated
filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule
12b-2
of the Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer
|
|
☐
|
|
Accelerated filer
|
|
☒
|
|
|
|
|
Non-accelerated
filer
|
|
☐
|
|
Smaller reporting company
|
|
☒
|
|
|
|
|
|
|
|
|
Emerging growth company
|
|
☒
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒
DEREGISTRATION OF SECURITIES
This Post-Effective Amendment No. 1 relates to the following Registration Statement on Form
S-8
(the Registration Statement) filed by Immune Design Corp., a Delaware corporation (the Company) with the Securities and Exchange Commission:
|
|
|
Registration
No. 333-217831,
filed on May 10, 2017, registering
1,016,522 shares of common stock of the Company, $0.001 par value per share, in connection with the Companys 2014 Omnibus Incentive Plan.
|
Pursuant to the Agreement and Plan of Merger, dated as of February 20, 2019 (the Merger Agreement), by and among the Company,
Merck Sharp & Dohme Corp., a New Jersey corporation (the Parent) and Cascade Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Parent (the Purchaser), the Purchaser merged with and into the
Company, with the Company continuing as the surviving corporation and a direct wholly owned subsidiary of Parent. As a result of the transactions contemplated by the Merger Agreement, the Company has terminated all offerings of its securities
pursuant to the Registration Statement and hereby removes and withdraws from registration all securities registered pursuant to the Registration Statement that remain unsold as of the date hereof. The Registration Statement is hereby amended, as
appropriate, to reflect the deregistration of such securities.
1
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe
that it meets all of the requirements for filing on Form
S-8
and has duly caused this Post-Effective Amendment No. 1 to the Registration Statement to be signed on its behalf by the undersigned, thereunto
duly authorized, in the City of Kenilworth, in the State of New Jersey, on this 2nd day of April, 2019.
|
|
|
IMMUNE DESIGN CORP. (REGISTRANT)
|
|
|
By:
|
|
/s/ Faye C. Brown
|
|
|
Name: Faye C. Brown
|
|
|
Title: Assistant Secretary
|
Pursuant to the Rule 478 of the Securities Act of 1933, as amended, no other person is required to sign
this Post-Effective Amendment No. 1 to the Registration Statement.
2
IMMUNE DESIGN CORP. (NASDAQ:IMDZ)
Historical Stock Chart
From Feb 2025 to Mar 2025
IMMUNE DESIGN CORP. (NASDAQ:IMDZ)
Historical Stock Chart
From Mar 2024 to Mar 2025
Real-Time news about Immune Design Corp. (NASDAQ): 0 recent articles
More Immune Design Corp. News Articles